Ginseng

Pharmacodynamic properties

The standardised ginseng extract G115 raises the general level of cellular activity, which is expressed by a pronounced increase in the physical and mental capacity.

In animal experiments, it caused a reduction of lactic acid concentration in muscles during exercise. An increase in the dopamine and noradrenaline content and a reduction in the serotonin content in the brain stem could be observed.

Pharmacokinetic properties

Pharmacokinetic studies of the standardised ginseng extract G115 are not possible, because it is a complex extract. In the ginseng root more than 200 substances have been identified to date. Pharmacokinetic studies of individual purified ginsenosides have been carried out in various animal species:

Using radioactively labelled (14C) Ginsenoside Rgl, originated from the standardized Panax ginseng extract G115, a bioavailability of 30% was determined in mice.

With intraperitoneal application, depending on the tested animal species and the Ginsenoside type, a half-life of between 27 minutes and 14.5 hours was measured.

Preclinical safety data

Acute toxicity

The oral LD50 of the standardized Panax ginseng extract G115 is more than 5 g/kg of body weight in the mouse and the rat, and more than 2 g/kg in the mini-pig.

Reproduction toxicity

The effect of standardized Panax ginseng extract G115 on reproductive performance was studied in two generations of Sprague-Dawley rats. Animals of both sexes were fed either control diet or diet supplemented with the standardized Panax ginseng extract G115 at dose levels of 1.5, 5 or 15 mg/kg body weight/day. Parameters of reproduction and lactation in the treated groups were comparable to those of the controls for two generations of dams and pups. No treatment-related effects were seen in weekly body weights and food consumption, haematological and blood chemistry parameters, and ophthalmic, macroscopic and histopathological examinations.

Fetal toxicity

The standardized Panax ginseng extract G115, administered to pregnant Wistar rats and pregnant New Zealand rabbits, caused no abnormality in the foetal development.

The rats were treated with 40 mg/kg/day from the 1st to the 15th day after mating.

The rabbits were treated with 20 mg/kg/day from the 7th to the 16th day after mating.

The fetuses were removed by caesarean section on the 21st day in the rats and on the 27th day in the rabbits.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.